Annexon, Inc. - common stock (NQ:ANNX)

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

September 24, 2026

Performance

52-Week Range 47.8% below 52-week high

3.750

2.5452W Low 7.1852W High

1 Week 7.9% below 1-week high

3.441W Low 4.071W High

Annexon, Inc. - common stock (ANNX) traded between $2.54 and $7.18 over the past 52 weeks and last traded at $3.75, 47.8% below its 52-week high. Over the past week it ranged between $3.44 and $4.07.

Past 12 Months

-6.5%

-3.1%

-28.2%

-36.2%

-20.0%

+23.0%

1W -$0.26

1M -$0.12

3M -$1.47

6M -$2.13

YTD -$0.94

1Y +$0.70

ANNX was +23.0% over the past year, -36.2% over six months, -20.0% year to date, -6.5% in the last week.

12 Months vs Market

ANNX

+23.0%

DIA

+11.6%

SPY

+13.1%

QQQ

+15.4%

IWM

+11.9%

Over the past 12 months ANNX returned +23.0% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.83× 3-mo avg

Today 2,575,610 3-mo avg 3.1M

4.8M

3.7M

3.1M

3.3M

YTD

3.0M

ANNX most recently traded 2,575,610 shares against a 3-month average daily volume of 3.1M.

More News

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

September 16, 2026

Annexon to Participate in Upcoming September Investor Conferences

September 02, 2026

Annexon (ANNX) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Via The Motley Fool

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2026

Annexon Q2 Earnings Call Highlights ↗

August 12, 2026

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

August 12, 2026

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

August 12, 2026

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

August 10, 2026

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

August 06, 2026

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

July 30, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

July 16, 2026

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

July 14, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

June 16, 2026

Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead ↗

June 09, 2026

Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout ↗

June 04, 2026

Annexon to Participate in Upcoming June Investor Conferences

May 27, 2026

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026

Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference ↗

May 14, 2026

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 07, 2026

Annexon to Present at the Bank of America Securities Health Care Conference 2026

May 06, 2026

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success

April 01, 2026

Via MarketMinute

March 30, 2026

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

March 16, 2026